Objectives
Sertoli-Leydig cell tumors (SLCTs) of the ovary are a rare subtype of sex cord-stromal tumor accounting for less than 0.5% of ovarian malignancies. Their management largely relies on surgery followed by adjuvant chemotherapy for high grade and advanced stage tumors; however the drugs of choice for treatment of initial and recurrent disease remain unknown. We aim to
systematically evaluate biomarkers from a relatively large cohort of SLCTs to explore therapeutic opportunities for this rare subtype of ovarian tumor.